Velocity Clinical Research Germany GmbH

At Velocity Clinical Research Germany GmbH in Ahrensburg, much of the clinical trial activity centers on respiratory tract diseases, especially asthma, chronic obstructive pulmonary disease, bronchiectasis, and idiopathic pulmonary fibrosis. These studies are largely designed to test new treatments, compare inhaled therapies, and assess how well they improve breathing, symptom control, and long-term lung health.

• Testing new options for moderate to severe asthma and uncontrolled asthma
• Evaluating treatment effectiveness in COPD, including exacerbation reduction and lung function
• Studying therapies for bronchiectasis and pulmonary fibrosis

Several trials also focus on safety, tolerability, and whether combination inhalers or biologic therapies can offer better control of chronic airway disease.

The site also contributes to research in digestive system diseases and nutritional and metabolic diseases, with studies such as those in irritable bowel syndrome. These trials aim to improve symptom relief, evaluate patient comfort, and determine the safety of new oral treatments for people living with ongoing gastrointestinal complaints.

• Assessing symptom improvement in irritable bowel syndrome
• Testing oral therapies for better digestive symptom control
• Monitoring safety and tolerability in gastrointestinal research

This area reflects a practical focus on treatments that may help reduce daily discomfort and improve quality of life for patients with chronic bowel symptoms.

Clinical trials at the site extend into nervous system diseases, immune system diseases, and virus diseases, including studies in cognitive impairment associated with post-COVID-19 syndrome. Research in this group looks at whether new therapies can improve cognition, reduce inflammation, and support recovery after infection or chronic immune-related illness.

• Investigating treatments for post-COVID cognitive impairment
• Exploring immune-targeted approaches for inflammatory disease
• Assessing whether therapies can improve recovery-related outcomes

These studies combine symptom-focused evaluation with broader efforts to understand how immune and neurological conditions may be managed more effectively.

The research portfolio at Velocity Clinical Research Germany GmbH also includes psychiatry and psychology, with studies in mild to moderate major depressive disorder. These trials are intended to determine whether new or existing treatments can reduce depressive symptoms, improve response rates, and support remission in people living with depression.

• Evaluating symptom improvement in major depressive disorder
• Comparing active treatment with placebo for mood outcomes
• Measuring response and remission in depressive disorders

The focus is on practical mental health outcomes that matter to patients, including how well treatment works in everyday life and how safely it can be used.